WO2011137160A3 - Composition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (ldl) per-oxidation in humans - Google Patents

Composition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (ldl) per-oxidation in humans Download PDF

Info

Publication number
WO2011137160A3
WO2011137160A3 PCT/US2011/034094 US2011034094W WO2011137160A3 WO 2011137160 A3 WO2011137160 A3 WO 2011137160A3 US 2011034094 W US2011034094 W US 2011034094W WO 2011137160 A3 WO2011137160 A3 WO 2011137160A3
Authority
WO
WIPO (PCT)
Prior art keywords
composition
per
ldl
humans
oxidation
Prior art date
Application number
PCT/US2011/034094
Other languages
French (fr)
Other versions
WO2011137160A2 (en
Original Assignee
U.S. Nutraceuticals, Llc D/B/A Valensa International
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/840,372 external-priority patent/US8481072B2/en
Priority claimed from US13/079,238 external-priority patent/US8557275B2/en
Priority claimed from US13/093,201 external-priority patent/US8663704B2/en
Application filed by U.S. Nutraceuticals, Llc D/B/A Valensa International filed Critical U.S. Nutraceuticals, Llc D/B/A Valensa International
Publication of WO2011137160A2 publication Critical patent/WO2011137160A2/en
Publication of WO2011137160A3 publication Critical patent/WO2011137160A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/286—Carthamus (distaff thistle)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/80—Scrophulariaceae (Figwort family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A composition and method which improves blood lipid profiles and optionally reduces low density lipoprotein (LDL) per-oxidation in humans by administering a therapeutic amount of a composition comprising krill oil in combination with astaxanthin or a mixture of fish oil derived, choline based, phospholipid bound omega-3 fatty acid mixture including phospholipid bound polyunsaturated EPA and DHA. In one embodiment, the krill oil is derived from Euphasia spp., comprising Eicosapentaenoic (EPA) and Docosahexaenoic (DHA) fatty acids in the form of triacylglycerides and phospholipids. The krill oil includes at least 10% EPA and 5% DHA, of which greater than 50% are in the form of phospholipids and the 1-4000 mg of krill oil per daily dose is delivered.
PCT/US2011/034094 2010-04-30 2011-04-27 Composition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (ldl) per-oxidation in humans WO2011137160A2 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US32974410P 2010-04-30 2010-04-30
US61/329,744 2010-04-30
US12/840,372 US8481072B2 (en) 2009-07-23 2010-07-21 Composition and method to alleviate joint pain
US12/840,372 2010-07-21
US13/079,238 US8557275B2 (en) 2009-07-23 2011-04-04 Composition and method to alleviate joint pain using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA
US13/079,238 2011-04-04
US13/093,201 2011-04-25
US13/093,201 US8663704B2 (en) 2010-04-30 2011-04-25 Composition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (LDL) per-oxidation in humans

Publications (2)

Publication Number Publication Date
WO2011137160A2 WO2011137160A2 (en) 2011-11-03
WO2011137160A3 true WO2011137160A3 (en) 2012-01-19

Family

ID=44352115

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/034094 WO2011137160A2 (en) 2010-04-30 2011-04-27 Composition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (ldl) per-oxidation in humans

Country Status (1)

Country Link
WO (1) WO2011137160A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107372861A (en) * 2017-08-24 2017-11-24 北京斯利安药业有限公司 A kind of composition and its application in the product for improving hyperlipemia is prepared

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2989078C (en) 2009-10-29 2020-06-30 Acasti Pharma, Inc. Concentrated therapeutic phosholipid compositions
WO2013033618A1 (en) 2011-09-02 2013-03-07 Arctic Nutrition As Lipid compositions with high dha content
CN109198042B (en) * 2018-10-22 2021-10-08 辽渔南极磷虾科技发展有限公司 high-EPA/DHA type antarctic krill oil phospholipid oral liquid and preparation method thereof
CN109439430B (en) * 2018-10-22 2021-10-08 辽渔南极磷虾科技发展有限公司 Euphausia superba oil refining method
BR112021010240A2 (en) * 2018-11-30 2021-08-17 Evonik Operations Gmbh preparation comprising a dispersion of phospholipids and fatty acid salts
CN114711321B (en) * 2022-03-19 2024-03-15 浙江新研坤科技有限公司 Euphausia superba oil gel candy added with plant omega 3 and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002090560A2 (en) * 2001-05-03 2002-11-14 Enzymotec Ltd. Process for the production of phospholipids
FR2835703A1 (en) * 2002-02-08 2003-08-15 Techniagro Production of oil and protein hydrolyzate for use, e.g., in foodstuffs from marine source such as filleting discards or fish heads and tail comprises enzymatic hydrolysis at specified temperature
WO2005037848A2 (en) * 2003-10-22 2005-04-28 Enzymotec Ltd. Glycerophospholipids containing omega-3 and omega-6 fatty acids
US20070098808A1 (en) * 2001-06-18 2007-05-03 Neptune Technologies & Bioressources Inc. Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases arthritis, skin cancer diabetes, premenstrual syndrome and transdermal transport

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60220415T2 (en) 2001-07-27 2008-02-14 Neptune Technologies & Bioressources Inc., Laval FLAVONOIDS AND MULTIPLE UNSATURATED NATURAL PHOSPHOLIPIDE MARITIME ORIGINS AND THEIR APPLICATIONS
US20090181114A1 (en) 2008-01-11 2009-07-16 U.S. Nutraceuticals, Llc D/B/A Valensa International Chia seed beverage and related method
US8586104B2 (en) 2008-04-10 2013-11-19 U.S. Nutraceuticals, LLC Plant derived seed extract rich in essentially fatty acids derived from Salvia hispanica L. seed: composition of matter, manufacturing process and use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002090560A2 (en) * 2001-05-03 2002-11-14 Enzymotec Ltd. Process for the production of phospholipids
US20070098808A1 (en) * 2001-06-18 2007-05-03 Neptune Technologies & Bioressources Inc. Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases arthritis, skin cancer diabetes, premenstrual syndrome and transdermal transport
FR2835703A1 (en) * 2002-02-08 2003-08-15 Techniagro Production of oil and protein hydrolyzate for use, e.g., in foodstuffs from marine source such as filleting discards or fish heads and tail comprises enzymatic hydrolysis at specified temperature
WO2005037848A2 (en) * 2003-10-22 2005-04-28 Enzymotec Ltd. Glycerophospholipids containing omega-3 and omega-6 fatty acids

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
ANN-MARIE LYBERG ET AL: "Enzymatic and chemical synthesis of phosphatidylcholine regioisomers containing eicosapentaenoic acid or docosahexaenoic acid", EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY, vol. 107, no. 5, 1 May 2005 (2005-05-01), pages 279 - 290, XP055012086, ISSN: 1438-7697, DOI: 10.1002/ejlt.200501138 *
BUNEA RUXANDRA ET AL: "Evaluation of the effects of Neptune Krill Oil on the clinical course of hyperlipidemia.", ALTERNATIVE MEDICINE REVIEW : A JOURNAL OF CLINICAL THERAPEUTIC DEC 2004 LNKD- PUBMED:15656713, vol. 9, no. 4, December 2004 (2004-12-01), pages 420 - 428, XP002656782, ISSN: 1089-5159 *
GRODJI A. GBOGOURI ET AL: "Analysis of lipids extracted from salmon (Salmo salar) heads by commercial proteolytic enzymes", EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY, vol. 108, no. 9, 1 September 2006 (2006-09-01), pages 766 - 775, XP055012082, ISSN: 1438-7697, DOI: 10.1002/ejlt.200600081 *
HARRIS W S: "Fish oils and plasma lipid and lipoprotein metabolism in humans: a critical review.", JOURNAL OF LIPID RESEARCH 1989 LIPID & ARTERIOSCLEROSIS PREVENTION CLINIC, DIV. OF CLINICAL PHARMACOLOGY, DEP. OF MED., UNIV. OF KANSAS MED. CENT., KANSAS CITY, KS 66103, USA, vol. 30, no. 6, 1989, pages 785, XP002656781 *
J PENG: "Polyunsaturated fatty acid profiles of whole body phospholipids and triacylglycerols in anadromous and landlocked Atlantic salmon (Salmo salar L.) fry", COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY PART B: BIOCHEMISTRY AND MOLECULAR BIOLOGY, vol. 134, no. 2, 1 February 2003 (2003-02-01), pages 335 - 348, XP055012248, ISSN: 1096-4959, DOI: 10.1016/S1096-4959(02)00263-4 *
KIDD P M: "Omega-3 DHA and EPA for cognition, behavior, and mood: Clinical findings and structural-functional synergies with cell membrane phospholipids", ALTERNATIVE MEDICINE REVIEW 200709 US, vol. 12, no. 3, September 2007 (2007-09-01), pages 207 - 227, XP002663709, ISSN: 1089-5159 *
KIM ET AL: "Phospholipase A1-catalyzed synthesis of phospholipids enriched in n-3 polyunsaturated fatty acid residues", ENZYME AND MICROBIAL TECHNOLOGY, STONEHAM, MA, US, vol. 40, no. 5, 8 March 2007 (2007-03-08), pages 1130 - 1135, XP005918029, ISSN: 0141-0229, DOI: 10.1016/J.ENZMICTEC.2006.08.018 *
LABORATOIRES LE STUM: "Le Vectomega", NUTRI-THEMA - LA LETTRE D'INFORMATION DES LABORATOIRES LE STUM, 1 December 2005 (2005-12-01), XP002663708, Retrieved from the Internet <URL:www.labo-lestum.fr/download.php?document=52NUTRITHEMA-Vecto-n%B07.pdf> [retrieved on 20111116] *
LINDER M ET AL: "Response surface optimisation of lipase-catalysed esterification of glycerol and n-3 polyunsaturated fatty acids from salmon oil", PROCESS BIOCHEMISTRY, ELSEVIER, NL, vol. 40, no. 1, 1 January 2005 (2005-01-01), pages 273 - 279, XP025306292, ISSN: 1359-5113, [retrieved on 20050101], DOI: 10.1016/J.PROCBIO.2004.01.014 *
MICHEL LINDER ET AL: "Proteolytic Extraction of Salmon Oil and PUFA Concentration by Lipases", MARINE BIOTECHNOLOGY, SPRINGER-VERLAG, NE, vol. 7, no. 1, 1 February 2005 (2005-02-01), pages 70 - 76, XP019368101, ISSN: 1436-2236 *
TOU J C ET AL: "Krill for human consumption: Nutritional value and potential health benefits", NUTRITION REVIEWS 200702 US LNKD- DOI:10.1111/J.1753-4887.2007.TB00283.X, vol. 65, no. 2, February 2007 (2007-02-01), pages 63 - 77, XP002644401, ISSN: 0029-6643 *
WIJENDRAN VASUKI ET AL: "EFFICACY OF DIETARY ARACHIDONIC ACID PROVIDED AS TRIGLYCERIDE OR PHOSPHOLIPID AS SUBSTRATES FOR BRAIN ARACHIDONIC ACID ACCRETION IN BABOON NEONATES", PEDIATRIC RESEARCH, WILLIAMS AND WILKINS, BALTIMORE, MD, US, vol. 51, no. 3, 1 March 2002 (2002-03-01), pages 265 - 272, XP009077737, ISSN: 0031-3998 *
WWW.KRILL-OIL-BENEFITS.COM: "Antioxidants: The "Free Radical Scavengers" Believed to Slow the Aging Clock and Protect Against Many Health Problems", 5 December 2008 (2008-12-05), XP002656785, Retrieved from the Internet <URL:http://web.archive.org/web/20081205014602/http://www.krill-oil-benefits.com/antioxidants.php> [retrieved on 20110812] *
WWW.KRILL-OIL-BENEFITS.COM: "Astaxanthin: The Super Antioxidant that Makes Neptune Krill Oil the Disease-Fighting, Inflammation-Fighting, PMS-Relieving, Anti-Aging Wonder Supplement for Every Body", 21 September 2008 (2008-09-21), XP002656784, Retrieved from the Internet <URL:http://web.archive.org/web/20080921180826/http://www.krill-oil-benefits.com/astaxanthin.php> [retrieved on 20110812] *
WWW.KRILL-OIL-BENEFITS.COM: "Krill Oil Cholesterol Study Brings Breakthrough Results", 23 December 2008 (2008-12-23), XP002656783, Retrieved from the Internet <URL:http://web.archive.org/web/20081223105203/http://www.krill-oil-benefits.com/krill-oil-cholesterol.php> [retrieved on 20110812] *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107372861A (en) * 2017-08-24 2017-11-24 北京斯利安药业有限公司 A kind of composition and its application in the product for improving hyperlipemia is prepared
CN107372861B (en) * 2017-08-24 2021-04-13 北京斯利安药业有限公司 Composition and application thereof in preparation of product for improving hyperlipidemia

Also Published As

Publication number Publication date
WO2011137160A2 (en) 2011-11-03

Similar Documents

Publication Publication Date Title
WO2011137160A3 (en) Composition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (ldl) per-oxidation in humans
AU2008231570B2 (en) Bioeffective krill oil compositions
HRP20171431T1 (en) Therapeutic application of parenteral krill oil
Kaur et al. Short-term docosapentaenoic acid (22: 5n-3) supplementation increases tissue docosapentaenoic acid, DHA and EPA concentrations in rats
WO2009091538A3 (en) Pharmaceutical composition comprising epa and dha for treating hypertriglyceridemia and hypercholesterolemia
NZ600167A (en) Concentrated therapeutic phospholipid compositions
NZ709083A (en) Eicosapentaenoic acid (epa) formulations
US20110268811A1 (en) Composition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (ldl) per-oxidation in humans
MX356427B (en) Hormone containing emulsion.
US20080113046A1 (en) Use of Omega-3 Fatty Acid(s) for Treating Hypercholesterolemia Caused by Anti-Retroviral Treatment of Hiv-Infected Patients
NZ626699A (en) Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
WO2006111633A3 (en) Use of lecithin as a medicament for treating psoriasis
WO2008147562A3 (en) Dietary formulations and methods for treatment of inflammation and other disorders
US8697676B2 (en) Omega-3 fatty acid nutriceutical composition and optimization method
WO2011097273A8 (en) Methods and compositions for treating non-alcoholic fatty liver disease with docosahexaenoic acid and n-acetyl l-cysteine
BRPI0418921A (en) use of polyunsaturated fatty acids, nutritional composition, and use of a
BRPI0512528A (en) use of polyunsaturated fatty acids, nutritional composition, and use of a composition
RU2013146517A (en) COMPOSITIONS AND METHODS SUITABLE FOR FACILITATION OF AGE DISEASES
WO2014045127A2 (en) Omega-3 phospholipid supplements for females
MX2013009007A (en) High protein nutritional compositions and methods of making and using same.
JP2014517028A5 (en)
JP2014505702A5 (en)
AR076184A1 (en) PHARMACEUTICAL FORMULATIONS THAT INCLUDE 9-CIS-RETINIL ESTERES IN A LIPID VEHICLE. METHOD.
MX2015007082A (en) Administering compositions comprising docosapentaenoic acid.
JP2016501248A5 (en)

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 6639/DELNP/2011

Country of ref document: IN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11717446

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11717446

Country of ref document: EP

Kind code of ref document: A2